プロテオミクスと単細胞プロファイリングは,ケラチン駆動の既存の免疫に影響を及ぼす肺状がんのネオアジュヴァント治療を特定する
Jiangnan Zhao1, Mo Shen1, Xia Xu2
1Department of Respiratory and Critical Care Medicine, Center for Oncology Medicine, The Fourth Affiliated Hospital of School of Medicine, International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China; Zhejiang Key Laboratory of Precision Diagnosis and Treatment for Lung Cancer, Yiwu, China.
Cancer letters
|August 24, 2025
まとめ
腫瘍のケラチニゼーションは肺がんの免疫療法への反応を予測する. 高いケラチニゼーションは抵抗を示し,低いケラチニゼーションはより良い結果と免疫細胞の浸透を示します.
科学分野:
- 腫瘍学
- 免疫療法
- バイオマーカーの発見
背景:
- 肺状細胞癌 (LUSC) は,ネオアジュバント免疫チェックポイント阻害に対する様々な反応を示しています.
- LUSCの治療決定を導くために,予測可能なバイオマーカーが必要です.
研究 の 目的:
- LUSCにおける免疫チェックポイントの阻害に対する反応を予測するバイオマーカーを特定する.
- 腫瘍のケラチニゼーションが治療抵抗性や患者のアウトカムにおける役割を調査する.
主な方法:
- 470人のLUSC患者の血清CYFRA21-1およびCK5/6免疫ヒストケミストリーの分析
- 患者を層分けするために167の治療先の生検のプロテオミックプロファイリング.
- 腫瘍の微小環境と細胞状態を分析するための単細胞RNAシーケンシング.
主要な成果:
- 血清のCYFRA21-1と高CK5/ 6の発現は,不完全な病理学的応答と残留腫瘍負担と相関する.
- 低ケラチニゼーション (KRT_ L) の患者は,免疫浸透が強化され,残留腫瘍が減少し,生存率が優れていた.
- 高いケラチニゼーション (KRT_H) 腫瘍は,ケラチンタンパク質の増加,代謝活性化,茎性の特徴,免疫抑制を示した.
結論:
- 腫瘍のケラチニゼーションは,LUSCにおける治療抵抗性の重要な決定因子です.
- ケラチニゼーションは,免疫冷却の微小環境,がんの根性,および免疫療法の有効性の低下と関連しています.
- ケラチンベースの分層化は,LUSC患者のパーソナライズされた治療を可能にします.
関連する概念動画
Targeted Cancer Therapies
7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.1K
Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Tumor Immunotherapy
2.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K


